SBSuzanne Broadgate

Suzanne Broadgate

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Suzanne Broadgate has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Stephanie Halford

    Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

    6 shared publications
  • Michel Michaelides

    UCL Institute of Ophthalmology, University College London, London, United Kingdom; Moorfields Eye Hospital, London, United Kingdom

    5 shared publications
  • Stephanie Halford

    Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neuroscience, University of Oxford, Level 6 John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK

    5 shared publications
  • Jing Yu

    Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

    4 shared publications
  • Richard Holt

    Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, United Kingdom

    4 shared publications
  • Andrew R. Webster

    UCL Institute of Ophthalmology, University College London, London, United Kingdom; Moorfields Eye Hospital, London, United Kingdom

    3 shared publications

Latest Publications

  • “Genetic and clinical findings in an ethnically diverse retinitis pigmentosa cohort associated with pathogenic variants in EYS”

    by Olivia Cundy, Suzanne Broadgate, Stephanie Halford, Robert E. MacLaren, Morag E. Shanks, Penny Clouston, Michael J. Gilhooley, Susan M. Downes

    Background and objectives The EYS gene is an important cause of autosomal recessive retinitis pigmentosa (arRP). The objective of this study is to report on novel pathogenic variants in EYS and the range of associated phenotypes. Subjects and methods This retrospective case series at a tertiary referral centre for inherited retinal diseases describes patients with an IRD and at least two variants in the EYS gene. Phenotyping included multimodal retinal imaging; genotyping molecular genetic analysis using targeted next generation sequencing. Sanger sequencing verification and analysis of novel variants using in silico approaches to determine their predicted pathogenicity. Results Eight male and four female patients were included. Age at onset ranged from 11 to 62 years with variable symptom presentation; ten patients showed classical features of retinitis pigmentosa, albeit with great variation in disease severity and extent. Two patients had atypical phenotypes: one with localised inferior sector pigmentation and a mild RP phenotype with changes predominantly at the posterior pole. Eighteen variants in EYS were identified, located across the gene: six were novel. Eight variants were missense, two altered splicing, one was a whole exon duplication and the remainder were predicted to result in premature truncation of the protein. Conclusion The marked variability in severity and age of onset in most patients in this ethnically diverse cohort adds to growing evidence that that mild phenotypes are associated with EYS variants. Similarly, the two atypical cases add to the growing diversity of EYS disease as do the six novel pathogenic variants described.


  • Open Access

    Association of Clinical and Genetic Heterogeneity With BEST1 Sequence Variations

    by Mital Shah, Suzanne Broadgate, Morag Shanks, Penny Clouston, Jing Yu, Robert E. MacLaren, Andrea H. Németh, Stephanie Halford, Susan M. Downes

    The range of phenotypes associated with sequence variations in BEST1 includes 5 clinically distinct retinal phenotypes: autosomal dominant best vitelliform macular dystrophy (BVMD) (otherwise known as vitelliform macular dystrophy), adult-onset vitelliform macular dystrophy (AVMD) (OMIM 608161), autosomal dominant vitreoretinochoroidopathy (ADVIRC) (OMIM 193200), autosomal recessive bestrophinopathy (ARB) (OMIM 611809), and autosomal dominant and recessive retinitis pigmentosa (RP) (OMIM 268000).1


  • Open Access

    Loss-of-Function Mutations in the CFH Gene Affecting Alternatively Encoded Factor H-like 1 Protein Cause Dominant Early-Onset Macular Drusen

    by Rachel L. Taylor, James A. Poulter, Susan M. Downes, Martin McKibbin, Kamron N. Khan, Chris F. Inglehearn, Andrew R. Webster, Alison J. Hardcastle, Michel Michaelides, Paul N. Bishop, et al.


    • 31 August 2018
      • Vol. 24, 603-612
    Open Access

    Novel homozygous splicing mutations in ARL2BP cause autosomal recessive retinitis pigmentosa

    by Alessia Fiorentino, Jing Yu, Gavin Arno, Nikolas Pontikos, Stephanie Halford, Suzanne Broadgate, Michel Michaelides, Keren J. Carss, F. Lucy Raymond, Michael E. Cheetham, et al.

    Purpose: Mutations in ARL2BP, encoding ADP-ribosylation factor-like 2 binding protein, have recently been implicated as a cause of autosomal recessive retinitis pigmentosa (arRP), with three homozygous variants identified to date. In this study, we performed next-generation sequencing to reveal additional arRP cases associated with ARL2BP variants. Methods: Whole-genome sequencing (WGS) or whole-exome sequencing (WES) was performed in 1,051 unrelated individuals recruited for the UK Inherited Retinal Disease Consortium and NIHR-BioResource Rare Diseases research studies. Sanger sequencing was used to validate the next-generation sequencing data, and reverse transcriptase (RT)-PCR analysis was performed on RNA extracted from blood from affected individuals to test for altered splicing of ARL2BP. Detailed phenotyping was performed, including clinical evaluation, electroretinography, fundus photography, fundus auto-fluorescence imaging, and spectral-domain optical coherence tomography. Results: Homozygous variants in ARL2BP (NM_012106.3) were identified in two unrelated individuals with RP. The variants, c.207+1G>A and c.390+5G>A, at conserved splice donor sites for intron 3 and intron 5, respectively, were predicted to alter the pre-mRNA splicing of ARL2BP. RT-PCR spanning the affected introns revealed that both variants caused abnormal splicing of ARL2BP in samples from affected individuals. Conclusions: This study identified two homozygous variants in ARL2BP as a rare cause of arRP. Further studies are required to define the underlying disease mechanism causing retinal degeneration as a result of mutations in ARL2BP and any phenotype-genotype correlation associated with residual levels of the wild-type transcript.


  • Diabetic macular oedema: under‐represented in the genetic analysis of diabetic retinopathy

    by Suzanne Broadgate, Christine Kiire, Stephanie Halford, Victor Chong

    Diabetic retinopathy, a complication of both type 1 and type 2 diabetes, is a complex disease and is one of the leading causes of blindness in adults worldwide. It can be divided into distinct subclasses, one of which is diabetic macular oedema. Diabetic macular oedema can occur at any time in diabetic retinopathy and is the most common cause of vision loss in patients with type 2 diabetes. The purpose of this review is to summarize the large number of genetic association studies that have been performed in cohorts of patients with type 2 diabetes and published in English‐language journals up to February 2017. Many of these studies have produced positive associations with gene polymorphisms and diabetic retinopathy. However, this review highlights that within this large body of work, studies specifically addressing a genetic association with diabetic macular oedema, although present, are vastly under‐represented. We also highlight that many of the studies have small patient numbers and that meta‐analyses often inappropriately combine patient data sets. We conclude that there will continue to be conflicting results and no meaningful findings will be achieved if the historical approach of combining all diabetic retinopathy disease states within patient cohorts continues in future studies. This review also identifies several genes that would be interesting to analyse in large, well‐defined cohorts of patients with diabetic macular oedema in future candidate gene association studies.


  • Open Access

    New variant and expression studies provide further insight into the genotype-phenotype correlation in YAP1-related developmental eye disorders

    by R. Holt, F. Ceroni, D. A. Bax, S. Broadgate, D. Gold Diaz, C. Santos, D. Gerrelli, N. K. Ragge

    YAP1, which encodes the Yes-associated protein 1, is part of the Hippo pathway involved in development, growth, repair and homeostasis. Nonsense YAP1 mutations have been shown to co-segregate with autosomal dominantly inherited coloboma. Therefore, we screened YAP1 for variants in a cohort of 258 undiagnosed UK patients with developmental eye disorders, including anophthalmia, microphthalmia and coloboma. We identified a novel 1 bp deletion in YAP1 in a boy with bilateral microphthalmia and bilateral chorioretinal coloboma. This variant is located in the coding region of all nine YAP1 spliceforms, and results in a frameshift and subsequent premature termination codon in each. The variant is predicted to result in the loss of part of the transactivation domain of YAP1, and sequencing of cDNA from the patient shows it does not result in nonsense mediated decay. To investigate the role of YAP1 in human eye development, we performed in situ hybridisation utilising human embryonic tissue, and observed expression in the developing eye, neural tube, brain and kidney. These findings help confirm the role of YAP1 and the Hippo developmental pathway in human eye development and its associated anomalies and demonstrate its expression during development in affected organ systems.


  • Open Access

    Identification and functional characterisation of genetic variants in OLFM2 in children with developmental eye disorders

    by R. Holt, S. A. Ugur Iseri, A. W. Wyatt, D. A. Bax, D. Gold Diaz, C. Santos, S. Broadgate, R. Dunn, J. Bruty, Y. Wallis, et al.

    Anophthalmia, microphthalmia, and coloboma are a genetically heterogeneous spectrum of developmental eye disorders and affect around 30 per 100,000 live births. OLFM2 encodes a secreted glycoprotein belonging to the noelin family of olfactomedin domain-containing proteins that modulate the timing of neuronal differentiation during development. OLFM2 SNPs have been associated with open angle glaucoma in a case–control study, and knockdown of Olfm2 in zebrafish results in reduced eye size. From a cohort of 258 individuals with developmental eye anomalies, we identified two with heterozygous variants in OLFM2: an individual with bilateral microphthalmia carrying a de novo 19p13.2 microdeletion involving OLFM2 and a second individual with unilateral microphthalmia and contralateral coloboma who had a novel single base change in the 5′ untranslated region. Dual luciferase assays demonstrated that the latter variant causes a significant decrease in expression of OLFM2. Furthermore, RNA in situ hybridisation experiments using human developmental tissue revealed expression in relevant structures, including the lens vesicle and optic cup. Our study indicates that OLFM2 is likely to be important in mammalian eye development and disease and should be considered as a gene for human ocular anomalies.


  • Open Access

    Characterization ofCDH3-Related Congenital Hypotrichosis With Juvenile Macular Dystrophy

    by Sarah Hull, Gavin Arno, Anthony G. Robson, Suzanne Broadgate, Vincent Plagnol, Martin McKibbin, Stephanie Halford, Michel Michaelides, Graham E. Holder, Anthony T. Moore, et al.

    First described in 2 brothers in 1935, congenital hypotrichosis with juvenile macular dystrophy (HJMD [OMIM 601553]) presents in childhood with central visual loss and associated abnormality of the scalp hair.1 Congenital HJMD is a rare, recessively inherited disorder reported to date in a total of 21 families with molecular confirmation and 15 different causative mutations.2-12 The disease is caused by biallelic loss of function mutations in the CDH3 gene (OMIM 114021), which encodes P-cadherin, a regulator of hair, retinal pigment epithelium (RPE), and limb development.2,7 Ectodermal dysplasia, ectrodactyly, and macular dystrophy syndrome (EEMS [OMIM 225280]) constitute an allelic disorder also associated with biallelic CDH3 mutations.13 The phenotype for EEMS is variable, with macular dystrophy; ectodermal involvement that includes hypotrichosis, nail dysplasia, and partial anodontia; and limb defects that include syndactyly (joined digits), campylodactyly (bent digits), or ectrodactyly (missing phalanges that, when most severe, has a claw-hand appearance). Only 6 families with molecular confirmation have been reported in the literature, with 5 additional pathogenic mutations in CDH3 identified.6,7,13,14


  • Open Access

    Hypotrichosis and juvenile macular dystrophy caused by CDH3 mutation: A candidate disease for retinal gene therapy

    by Mandeep S. Singh, Suzanne Broadgate, Ranjana Mathur, Richard Holt, Stephanie Halford, Robert E. MacLaren

    Hypotrichosis with juvenile macular dystrophy (HJMD) is an autosomal recessive disorder that causes childhood visual impairment. HJMD is caused by mutations in CDH3 which encodes cadherin-3, a protein expressed in retinal pigment epithelium (RPE) cells that may have a key role in intercellular adhesion. We present a case of HJMD and analyse its phenotypic and molecular characteristics to assess the potential for retinal gene therapy as a means of preventing severe visual loss in this condition. Longitudinal in vivo imaging of the retina showed the relative anatomical preservation of the macula, which suggested the presence of a therapeutic window for gene augmentation therapy to preserve visual acuity. The coding sequence of CDH3 fits within the packaging limit of recombinant adeno-associated virus vectors that have been shown to be safe in clinical trials and can efficiently target RPE cells. This report expands the number of reported cases of HJMD and highlights the phenotypic characteristics to consider when selecting candidates for retinal gene therapy.